PNC-27: A Novel Effective Strategy for Targeting the Achilles’ Heel of Multiple Myeloma

Basic Information

Funding Cycle : 2021-2022
Name : Guido Marcucci
Type of Award : Translational Research Award
Home Institution : City of Hope


The project focuses on using the anticancer peptide PNC-27, which targets the p53 pathway, as a potential therapeutic approach for multiple myeloma (MM). While MM with high-risk features like TP53 deletion has poorer outcomes, PNC-27 has shown promising results in cancer cells, including MM, by inducing cell death. Despite the absence of MDM2 on MM cell membranes, PNC-27 effectively penetrates MM cells’ cytoplasm, exerting potent killing effects. The study aims to understand how PNC-27 affects MM cells’ mitochondrial function, metabolism, and signaling pathways, hypothesizing that it induces mitochondrial damage and oxidative stress, leading to MM cell death. Additionally, the project aims to evaluate PNC-27’s pharmacokinetics, pharmacodynamics, and anti-MM activity in a mouse model, aiming to determine optimal doses and schedules for effective treatment.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events